Intraperitoneal Chemotherapy
Enhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MorePrognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers
Annals of Surgical Oncology 2024 November 13 [Link] Xin-Li Liang, Yan-Dong Su, Xin-Bao Li, Yu-Bin Fu, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract Objectives: This study was designed to explore the survival benefit factors of malignant peritoneal mesothelioma (MPM) patients after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to…
Read MorePerfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Journal of Surgical Oncology 2024 September 10 [Link] Claire Drigotas, Alexander W Loftus, John B Ammori, Luke D Rothermel, Richard S Hoehn Abstract Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to…
Read MoreDrug sensitivity tumor cell clusters in malignant peritoneal mesothelioma
Journal of Surgical Oncology 2024 August 24 [Link] Yan-Dong Su, Ru Ma, Yu-Bin Fu, He-Liang Wu, Xin-Li Liang, Yi-Tong Liu, Yang Yu, Zhi-Ran Yang, Yan Li Abstract Background: To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor-like cell clusters (PTC) drug sensitivity test. Methods: PTC were cultured…
Read MoreStemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei
International Journal of Cancer 2024 August 15 [Link] Nayana Lazzari, Giulia Rigotto, Barbara Montini, Paola Del Bianco, Elena Moretto, Federica Palladino, Rocco Cappellesso, Marco Tonello, Carola Cenzi, Antonio Scapinello Maria Assunta Piano, Carlo Riccardo Rossi, Piero Dalerba, Pierluigi Pilati, Antonio Sommariva, Maria Luisa Calabrò Abstract Intrabdominal dissemination of malignant mesothelioma (MM) and pseudomyxoma peritonei (PMP)…
Read MoreCurrent clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Innovative Surgical Sciences 2024 March 14 [Link] Miklos Acs, Maximilian Babucke, Maximilian Jusufi, Zsolt Kaposztas, Przemyslaw Slowik, Matthias Hornung, Hans J Schlitt, Ivan Panczel, Judit Hevesi, Jonas Herzberg, Tim Strate, Pompiliu Piso Abstract Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled problems, as there are many uncertain aspects considering the outcomes of…
Read MoreA systematic review of minimally invasive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy
ANZ Journal of Surgery 2024 May 15 [Link] Lauren Cohen, Faizah Alam, Michael P Flood, Helen Mohan, Anshini Jain, Glen Guerra, Alexander G Heriot, Joseph C H Kong Abstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is traditionally a maximally invasive operation with a large abdominal incision and multi-visceral resections. However, to minimize…
Read MoreThe role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany
Langenbeck’s Archives of Surgery 2024 April 8 [Link] Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki , Andreas Pascher, Judith C Sporn Abstract Purpose: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy…
Read MoreIs extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read More